A method of generating an internally fixed lipid vesicle, comprising: providing a precursor lipid vesicle that contains an aqueous interior enclosed by a lipid membrane, wherein the lipid membrane of the precursor lipid vesicle is non-permeable to a crosslinker; permeabilizing the lipid membrane transiently to generate a permeable vesicle; contacting the permeable vesicle with an inactive activatable crosslinker, whereby the inactive activatable crosslinker enters the permeable vesicle; allowing the permeable vesicle to return to a non-permeable vesicle; removing any extravesicular crosslinker; and activating the inactive activatable crosslinker to allow crosslinking to occur inside the non-permeable vesicle, whereby an internally fixed lipid vesicle is generated.

Provided is a technology useful for verifying measurement accuracy before measurement of an electrical characteristic of blood samples.

A sample for use in electrical characteristic measurement is provided including erythrocytes incompletely fixed with a fixative, the fixed erythrocytes being such that an electrical characteristic of a mixture of the fixed erythrocytes and plasma components can change over time. An electrical characteristic measurement method is provided including measuring an electrical characteristic of the sample for use in electrical characteristic measurement over time before measuring an electrical characteristic of blood samples over time. An electrical characteristic measurement device is provided including a determination unit configured to determine measurement accuracy on the basis of a predetermined reference value and measured values based on the electrical characteristic measured using the sample for use in electrical characteristic measurement.

Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.

Disclosed herein is an internally fixed lipid vesicle generated from a cell that substantially preserves the membrane characteristics of the cell and methods of using the internally fixed lipid vesicle.

Disclosed herein is an internally fixed lipid vesicle generated from a cell that substantially preserves the membrane characteristics of the cell and methods of using the internally fixed lipid vesicle.

Methods, compositions, systems, and devices are provided for performing and analyzing agglutination assays. In one aspect, methods for image analysis of agglutination assays are provided. In another aspects, methods for performing agglutination assays are provided. In one aspect, the methods may be used for the detection of various molecules, including viruses or antibodies against a virus. In another aspect, the methods can be used to determine effective immunization of a subject.

Provided is a biomaterial detection sensor. The biomaterial detection sensor comprises a substrate and a detection probe including a metal nanoparticle deposited on the substrate, and an erythrocyte membrane conformally covering the metal nanoparticle, wherein the detection probe may selectively react with fibrinogen.

Provided is a biomaterial detection sensor. The biomaterial detection sensor comprises a substrate and a detection probe including a metal nanoparticle deposited on the substrate, and an erythrocyte membrane conformally covering the metal nanoparticle, wherein the detection probe may selectively react with fibrinogen.

The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, Staphylococcal protein A, as well as methods of making and using such ligands.